BioVaxys Technology AI Stock Analysis
Want to see TSE:BIOV full AI Analyst Report?
BioVaxys Technology (BIOV) AI Stock Analysis
BioVaxys Technology
(CNQX:BIOV)
BioVaxys Technology faces severe financial challenges, with no revenue and reliance on external financing, which heavily impacts its overall score. Technical analysis indicates weak momentum and a bearish trend, while the negative valuation metrics highlight the risks involved. However, the company is taking steps towards financial management and exploring new market opportunities, which could improve its future prospects.
BioVaxys Technology (BIOV) vs. iShares MSCI Canada ETF (EWC)
- Market Cap
- CAD 2.62M
- Dividend Yield
- ―
- Average Volume (3M)
- ―
- Price to Earnings (P/E)
- -0.3
- Beta (1Y)
- 1.23
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- Canada
- Employees
- 3
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
BioVaxys Technology Business Overview & Revenue Model
Company Description
BioVaxys Technology Corp. is a clinical-stage biotechnology company specializing in the development of vaccine platforms designed to combat both viral infections and cancer. The company's pipeline includes BVX-0320, a single-strain vaccine for SARS-C...
How the Company Makes Money
BioVaxys Technology generates revenue primarily through the development and commercialization of its vaccine candidates. The company aims to monetize its proprietary haptenized vaccines through licensing agreements, partnerships with pharmaceutical c...
BioVaxys Technology Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:BIOV, the sentiment is Positive. The current price of 0.07 is above the 20-day moving average (MA) of 0.07, above the 50-day MA of 0.07, and below the 200-day MA of 0.08, indicating a neutral trend. The MACD of 0.00 indicates Positive momentum. The RSI at 54.05 is Neutral, neither overbought nor oversold. The STOCH value of 0.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:BIOV.
BioVaxys Technology Peers Comparison
Overall Rating
TSE:DTC44Neutral
TSE:ARCH43Neutral
TSE:BCT42Neutral
TSE:MDNA40Underperform
TSE:VXL37Underperform- TSE:BIOV28.5Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| TSE:DTC | 44Neutral | CAD 25.50M | -2.81 | -424.91% | ― | ― | -54.70% |
| TSE:ARCH | 43Neutral | CAD 63.86M | -21.65 | 74.79% | ― | ― | -15.53% |
| TSE:BCT | 42Neutral | CAD 45.41M | -0.38 | -170.70% | ― | ― | 87.90% |
| TSE:MDNA | 40Underperform | CAD 30.66M | -1.88 | -360.29% | ― | ― | -33.27% |
| TSE:VXL | 37Underperform | CAD 438.24K | 1.10 | 34.52% | ― | ― | ― |
| TSE:BIOV | 29Underperform | CAD 2.04M | -0.35 | 149.46% | ― | ― | ― |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TSE:BIOV | Biovaxys Technology Corp | 0.07 | -0.19 | -73.08% | |
| TSE:ARCH | Arch Biopartners | 0.92 | -0.10 | -9.80% | |
| TSE:MDNA | Medicenna Therapeutics | 0.41 | -0.96 | -69.71% | |
| TSE:BCT | BriaCell Therapeutics | 5.08 | -8.67 | -63.05% | |
| TSE:VXL | Vaxil Bio | 0.11 | -0.06 | -35.29% | |
| TSE:DTC | Defence Therapeutics Inc | 0.34 | -0.52 | -61.05% |
BioVaxys Technology Corporate Events
BioVaxys and SpayVac Expand License to Target Aquaculture Market
PositiveBioVaxys Technology Corp. and SpayVac for Wildlife, Inc. have expanded their license agreement to include commercial aquaculture, targeting the farm-raised fish market with their no-booster fertility-control vaccines. This expansion presents a signif...
BioVaxys Technology Corp. Revokes Cease Trade Order and Settles Debt
PositiveBioVaxys Technology Corp. announced the revocation of a management cease trade order by the British Columbia Securities Commission following the completion of its required financial filings. Additionally, the company has settled a debt of $60,000 by...
BioVaxys Technology Corp. Announces Debt Settlement to Optimize Financial Operations
PositiveBioVaxys Technology Corp. has announced a debt settlement agreement with THECCSGROUP, where it will issue 1,200,000 common shares to settle a $60,000 debt. This strategic move aims to preserve the company’s cash for working capital, reflecting a focu...
BioVaxys Technology Corp. Updates on Management Cease Trade Order Status
NeutralBioVaxys Technology Corp. has announced a bi-weekly update regarding a management cease trade order (MCTO) due to delays in filing its audited annual financial statements. The company is working with its auditor to complete the filings by March 30, 2...
BioVaxys Technology Corp. Receives Management Cease Trade Order Amid Filing Delays
NegativeBioVaxys Technology Corp. has been granted a management cease trade order (MCTO) by the British Columbia Securities Commission due to a delay in filing its audited annual financial statements and related documents. The delay is attributed to the rece...
BioVaxys Settles Debt and Closes Final Private Placement Tranche
PositiveBioVaxys Technology Corp. has announced a debt settlement agreement with consultants by issuing shares to preserve cash for working capital. Additionally, the company extended its private placement closing date and closed its final tranche, raising $...
BioVaxys Faces Potential Filing Delay Amid Recent Acquisitions
NeutralBioVaxys Technology Corp. has announced a potential delay in filing its annual financial statements due to the complexities involved in auditing its recent acquisition of intellectual property and assets from IMV Inc. The company is proactively seeki...
BioVaxys Extends Private Placement Closing Date to February 14, 2025
PositiveBioVaxys Technology Corp. has announced an extension to the closing date of its non-brokered private placement offering, originally set for February 7, 2025, and now extended to February 14, 2025. This extension aims to allow additional investors to...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Apr 29, 2025